Abstracts tagged "Scleroderma"

Abstract Number: 1370 • ACR Convergence 2021
Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Roberta G Marangoni¹, Changyong Feng¹, Ashley Frazer-Abel², Stephen Tomlinson³, Amy Wielgosz¹, Katie Lutz⁴, Michael Pauciulo⁴, William Nichols⁴, V. Michael Holers⁵, Christopher Ritchlin⁶, R James White III¹ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Colorado Denver, Colorado, CO, ³Medical University of South Carolina, Charleston, SC, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University of Colorado, Denver, CO, ⁶Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe vascular complication of systemic sclerosis (SSc) and a major cause of mortality. Despite significant advances in the…
Abstract Number: 1856 • ACR Convergence 2021
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
Ranjitha Karanth¹, Giuseppina Abignano², Vishal Kakkar², Rebecca Ross², Christopher Denton³ and Francesco Del Galdo², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…
Abstract Number: 1371 • ACR Convergence 2021
Symptom Management in Systemic Sclerosis: A Pilot Study of a Web-based Intervention Using Peer-Health Coaches
Susan Murphy¹, Yen Chen², Mary Alore², Sheri Hicks² and Dinesh Khanna², ¹University of Michigan, Grosse Ile, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: People with systemic sclerosis (SSc) have a high burden of chronic symptoms that have dramatic effects on function and quality of life. Fatigue, along…
Abstract Number: 0142 • ACR Convergence 2021
Description of a Scleroderma Cohort and Management of Lung Disease Risk at a Rural Academic Medical Center
Jenna Marinock¹, P. Daniel Nicholas², Kirsten Koons³, Rakesh Kriplani⁴, Andrea Berger⁴ and David Bulbin⁵, ¹Geisinger Commonwealth School of Medicine, Philadelphia, PA, ²Geisinger Medical Center, Danville, PA, ³Geisinger Medical Center, Lewisburg, PA, ⁴Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, ⁵Geisinger Health System, Danville, PA
Background/Purpose: Systemic sclerosis interstitial lung disease (SSc-ILD) and pulmonary hypertension (SSc-PH) are leading causes of morbidity and mortality in patients with SSc. Few screening guidelines…
Abstract Number: 1372 • ACR Convergence 2021
Outcomes and Risk Factors for Respiratory Failure in Patients with Scleroderma Associated with ILD
Soumyasri Kambhatla¹, Augustine Manadan² and Amy Trang², ¹Rush University, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Scleroderma is associated with underlying ILD. About 48% those with diffuse cutaneous SSc and 26% of those with limited cutaneous SSc were found to…
Abstract Number: 0391 • ACR Convergence 2021
High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time
Elizabeth Marjanovic¹, Calvin Heal¹, Tonia Moore¹, Joanne Manning², Sarah Wilkinson¹, Graham Dinsdale², Mark Dickinson¹, Jack Wilkinson¹, Ariane Herrick³ and Andrea Murray¹, ¹University of Manchester, Manchester, United Kingdom, ²Salford Royal NHS Foundation Trust, Manchester, United Kingdom, ³University of Manchester, Salford, United Kingdom
Background/Purpose: There are currently no validated objective measures of systemic sclerosis (SSc)-related skin thickening and this hampers clinical trials of potential new treatments. The modified…
Abstract Number: 1377 • ACR Convergence 2021
Assessment of Autoantibodies and Clinical Associations in SSc Patients with ANA Positivity & Negative for Prototypic Autoantibodies
Karen Kruzer¹, Roberta G Marangoni¹, Ilana Heckler², Aya Elhage², Varga John³, Monique Hinchcliff⁴, Mary Carns⁵, Kathleen Aren⁵, Amy Wielgosz¹, Marc Nuzzo⁶, Iswariya Venkataraman² and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²EUROIMMUN US, Mountain Lakes, NJ, ³University of Michigan, Ann Arbor, MI, ⁴Yale School of Medicine, Westport, CT, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic sclerosis (SSc) is a clinically heterogenous disease typically characterized by a positive ANA (ANA+), and prototypical antibodies including anti-centromere, anti-topoisomerase, and anti-RNA polymerase…
Abstract Number: 0392 • ACR Convergence 2021
Faecal Incontinence in Scleroderma: Prevalence, Impact and Response to Sacral Neuromodulation in an Single Centre Observational Cohort
Nikhil Suresh¹, Ranjitha Karanth¹, David Jayne², Giuseppina Abignano³ and Francesco Del Galdo³, ¹LIRMM, Leeds, United Kingdom, ²Colorectal Surgery / St James University Hospital, Leeds, United Kingdom, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Scleroderma (SSc) is a chronic autoimmune disorder involving multiple organs, the gastrointestinal system (GI) commonly involved in up to 90% of the sufferers. Faecal…
Abstract Number: 1378 • ACR Convergence 2021
Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort
Matthew Kirkpatrick¹, Janet Lee¹, Anne Tebo², Haojia Li¹, yue zhang¹ and Tracy Frech¹, ¹University of Utah, Salt Lake City, UT, ²Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Autoantibodies are included in the disease classification criteria for systemic sclerosis (SSc). Our group previously reported the level of topoisomerase autoantibody as an important…
Abstract Number: 0395 • ACR Convergence 2021
RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon
Megan Lockwood¹, Yuqing Zhang², Marcy Bolster¹, Sara Schoenfeld¹, Xiaoqing Fu¹, Seth Brownmiller¹, Ana Fernandes¹ and Flavia Castelino¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA
Background/Purpose: Raynaud phenomenon is often the initial manifestation in systemic sclerosis (SSc) and can precede other SSc symptoms by years (1). Several SSc-specific autoantibodies are…
Abstract Number: 1380 • ACR Convergence 2021
Quality of Life in Patients with Scleroderma Associated Calcinosis Cutis: A Cross-Sectional Study
Aditi Patel¹, Mehnaj Grewal², Robert Butler² and Soumya Chatterjee³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Calcinosis cutis (CC) can commonly affect patients with systemic sclerosis (SSc), which is often painful, resulting in functional impairment and morbidity. A radiographic scoring…
Abstract Number: 0405 • ACR Convergence 2021
Retrospective Study on the Prognostic Value of Cardiac Magnetic Resonance Imaging Abnormalities in Systemic Sclerosis
Hao Cheng Shen¹, Catherine Faucher², Anne Chin³, Carl Chartrand-Lefebvre³, Ragui Chehata⁴, Julia Cadrin-Tourigny⁵, Francois-Pierre Mongeon⁶, Jean-Paul Makhzoum⁷, Océane Landon-Cardinal⁸, Josiane Bourré-Tessier⁸, Éric Rich⁹, Jean-Richard Goulet⁸, Paul R Fortin¹⁰, Jean-Luc Senécal⁸ and Sabrina Hoa⁸, ¹Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Department of Medicine, Université Laval, Québec, QC, Canada, ³Department of Radiology, Centre hospitalier de l’Université de Montréal, Montréal, QC, Canada, ⁴Department of Medicine, Université de Montréal, Montreal, Montréal, QC, Canada, ⁵Division of Non-Invasive Cardiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁶Division of electrophysiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁷Division of Internal Medicine, Hôpital Sacré-Coeur de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁸Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁹Division of Rheumatology, Centre hospitalier de l’Université de Québec-Université Laval, Montréal, QC, Canada, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Cardiac involvement is a leading cause of death in systemic sclerosis (SSc). Cardiac MRI (CMR) is useful in the early assessment of cardiac disease.…
Abstract Number: 1381 • ACR Convergence 2021
Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis
Imon Barua¹, Håvard Fretheim², Hilde Jenssen Bjørkekjær³, Henriette Didriksen⁴, Oyvind Midtvedt², Trond Mogens AAløkken², Torhild Garen⁵, Oyvind Molberg⁶, John Belperio⁷ and Anna-Maria Hoffmann-Vold¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Sørlandet sykehus HF, Kristiansand, Norway, ⁴Oslo University Hospital, Moss, Norway, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Nepal, ⁶Oslo University Hospital, Oslo, Nepal, ⁷University of California Los Angeles Interstitial Lung Disease Center, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD). Several anti-inflammatory therapies have been used to treat SSc-ILD and recently the…
Abstract Number: 0412 • ACR Convergence 2021
Prevalence, Distribution, Clinical Correlates and Outcomes of Upper Extremity Macrovascular Disease in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
Ashima Makol¹, Caitrin Coffey¹, Tina Gunderson¹, Alicia Hinze¹, Yasser Radwan², Cynthia Crowson³, David Liedl¹, Kenneth Warrington¹ and Paul Wennberg¹, ¹Mayo Clinic, Rochester, MN, ²Michigan State University, Lansing, MI, ³Mayo Clinic, Eyota, MN
Background/Purpose: To study the prevalence, anatomical distribution, clinical correlates and outcomes of macrovascular disease (MVD) on duplex ultrasound (US) of the upper extremity in Systemic…
Abstract Number: 1388 • ACR Convergence 2021
Heterogeneity of Primary and Secondary Peristalsis in Systemic Sclerosis: A New Model of Scleroderma Esophagus
John Pandolfino¹, Harris Perlman¹, Monique Hinchcliff², Mary Carns³, John Pandolfino¹, John Pandolfino¹, Chase Correia¹ and John Pandolfino¹, ¹Northwestern University, Chicago, IL, ²Yale School of Medicine, Westport, CT, ³Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Although esophageal dysmotility is common in systemic sclerosis (SSc), little is known regarding the pathophysiology of the motor abnormalities driving reflux severity and dysphagia.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].